DrBecher

interventional & clinical cardiologist & trialist

[Edgar Argulian @argulian]

Most echocardiography laboratories have adopted the 2016 diastolic guidelines. With the release of the 2025 update, an important question arises:
What are the key conceptual differences between the 2016 and 2025 approaches to diagnosing diastolic dysfunction?

https://t.co/FPkUqRtmYd

@JGrapsa

[Sunil V. Rao @SVRaoMD]

Door-to-defecation time…

Defecation Patterns and Cardiovascular Outcomes in Acute Coronary Syndrome: The Influence of Stimulant Laxative Use
https://t.co/wypacDc2aH

[Cristobal Morales @CristobMorales]

https://t.co/1VKXNrpRFa Aprobación EMA 🇪🇺 Del primer GLP1 oral para el tratamiento del sobrepeso y obesidad. 2026 el inicio de la democratización y el uso más accesible que nos permitirá llegar antes y utilizarlo en el mantenimiento #WegovyPill @NovoNordiskES @SociedadSeedo

[Almudena Castro Conde @almucastro01]

Lo que viene en tratamiento de la enfermedad metabólica adiposa crónica (antes llamada obesidad) era inimaginable hace pocos años.

Si crees que retratutide era la 💣.
Léete este artículo del
Quíntuple‼️ agonismo:

GLP-1R–GIPR–PPARα/γ/δ quintuple agonism
corrects obesity and diabetes in mice

¿Cuál será su impacto en los resultados cardiovasculares?
Nos queda tiempo para saberlo, pero no tanto.

https://t.co/NhSakIfTsN

[Yoni Freedhoff @YoniFreedhoff]

Wow! Lilly Triumph-1 outcomes published today show retatrutide delivering an average 30.3% weight loss at 104 weeks. That's bariatric surgery level loss. https://t.co/xc5kp6DGoK

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Great news for weight loss maintenance with incretin therapy:

ATTAIN-MAINTAIN: #orforglipron achieved the primary & all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound

Those switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average!
@EliLillyandCo has submitted orforglipron to @US_FDA for the treatment of obesity #CVprev #obesity #weightloss
📎 https://t.co/n7reSHWzc4

[Cristobal Morales @CristobMorales]

https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial #ECO2026

[Evandro Martins F. MD @evandrofilhobr]

Burr entrapment, one of the most feared complications in rotational atherectomy. Multiple bailouts, choice driven by operator experience. Algorithms help organize the toolbox, especially for less experienced operators. My usual path: step (2) vasodilator + gentle pull (solves most), then (5) wire + balloon next to the burr or (6) knuckle wire for the resistant ones. With step (3), skipping rope, a newer iterative technique, I'll probably start following this more logical sequence.
#CHIP #Rotablator #RA #atherectomy #entrapment

[Transcatheter Interventions Online @TIOCongress]

PE thrombectomy tip ⚡

Dr Pablo Salinas Sanguino walks through:
➡️ Crossing the tricuspid valve
➡️ Why he starts from the right PA
➡️ Triever24 set-up strategy

Simple workflow details. Major procedural impact.

#PulmonaryEmbolism #PE #TIOCongress

[EuroIntervention @EuroInterventio]

DCB use in de novo PCI is expanding, but optimal guidance remains unclear.
This viewpoint discusses the potential role of intracoronary imaging to guide lesion selection, preparation, and optimisation—highlighting key evidence gaps.

https://t.co/WuFZv112pb

@NievesGonzalo1 @nicolasamabile
#CardioTwitter #PCI

[Paul Wischmeyer MD @Paul_Wischmeyer]

Walking ~7000 steps/day vs. ~2000 steps/day is associated with:
- 47% lower all-cause mortality
- 47% lower cardiovascular disease mortality
- 37% lower cancer mortality
- 38% lower dementia risk
- 22% lower depression

If you care about your health, start walking.

[Michael Megaly @MichaelMegalyMD]

A backtable illustration of a couple techniques you can use if the #Rotaburr gets stuck,

1-The skipping rope technique.
We have known it for a couple years, and it was recently published

https://t.co/fqTn6NXkaT

2-The final resort of cutting the rota driveshaft and advance a guideliner through it to get more leverage to pull.

Of course the first thing you do is to pull hard and maybe try to balloon around it, but those can help with tougher situations.

#CardioX community, please share your additional tips and comments

[Eric Topol @EricTopol]

Why is there such obsession with extending lifespan when the bigger issue is that average healthspan is 65 years and there are no data (except in super-centenarians) that longer lifespan = longer healthspan (known as compression of morbidity)?

[Davide Capodanno @DFCapodanno]

Can artificial intelligence detect coronary plaque progression before it becomes clinically evident? This is the first deep-learning model designed to detect changes in plaque progression by quantifying frame-to-frame changes in plaque burden across adjacent IVUS images. https://t.co/bZti6jVp1B

[Davide Capodanno @DFCapodanno]

This state-of-the-art review provides a comprehensive overview of the pathophysiological mechanisms underlying the no-reflow/slow-flow phenomenon, covering invasive and non-invasive diagnostic tools, pharmacological and interventional treatment strategies, and the key clinical gaps that still need to be addressed in the field. https://t.co/glYW3u2X2z

[Richard Sohn MD @RSohnMD]

2/ This is intra-plaque hemorrhage (IPH), occurring inside of INTIMA

This crescent blood pool clearly resides NOT outside of media (dark stripe, blue arrow) but rather within the very eccentric fibrous plaque (green borders)

[JACC Journals @JACCJournals]

In the randomized KISS trial of non-LM bifurcations, a conservative strategy without systematic side branch (SB) intervention was noninferior to a systematic SB intervention regarding periprocedural myocardial infarction & myocardial injury. https://t.co/vKpEix9Tjr #JACCINT #cvMI

[Ahmed Bennis MD 🫀 @drbennisahmed]

Did you know Lp(a) levels can DOUBLE during a healthy pregnancy — and rise again at menopause? 📈
New research highlights how lipoprotein(a) fluctuates throughout a woman’s life, and why that matters for cardiovascular risk.
We still have major gaps to fill:
• Does rising Lp(a) at menopause drive CVD risk — or is it lifetime exposure?
• Does HRT help or hurt?
• How does race/ethnicity shape Lp(a) in pregnancy?
Women’s hearts deserve sex-specific science. 🫀
Michos ED, et al. JACC Adv. 2026 👇
https://t.co/AxHvYq4Vfp

#Lpa #Lipoprotein #CardiovascularResearch #JACC #Lipidology #CVDRisk #PreventiveCardiology

[Gregor Leibundgut @swissCTO]

@realarainmd This is an excellent indication for the RIP technique!
https://t.co/Q9o8bRLebs

[Ahmed Bennis MD 🫀 @drbennisahmed]

Without treatment, 2-year mortality in HFrEF is 35%. With all 4 evidence-based therapies? 9.5%. 🧵
📉 Cumulative impact of GDMT on 2-year mortality:
❌ None — 35.0%
💊 + ARNI — 25.2% (↓28%)
💊 + Beta Blocker — 16.4% (↓35%)
💊 + Aldosterone Ant. — 11.5% (↓30%)
💊 + SGLT2i — 9.5% (↓17%)
Total: 72.9% relative risk reduction | 25.5% absolute risk reduction | NNT = 4
Treating just 4 patients with full GDMT saves 1 life over 2 years. That’s among the most powerful NNTs in all of medicine.
And all 4 drugs are now available as generics for ~$420/year. The evidence and the access are both there.
#HeartFailure #HFrEF #GDMT #CardioTwitter #EvidenceBasedMedicine #NNT​​​​​​​​​​​​​​​​
@gcfmd @SJGreene_md @AndrewJSauer @mvaduganathan @safchat @GianluSava @BiykemB @JavedButler1 @ankeetbhatt @hfcollaboratory